1
After losing 25 of its members to stomach cancer in 30 years, a Maori family put aside traditional superstitions and contacted laboratories throughout New Zealand to obtain a scientific explanation. The study they initiated has identified a germline mutation in the gene that codes for E-cadherin (E-cad), an epithelial cell adhesion molecule (Fig. 1). The mutation causes a reduction in the amount of functional E-cadherin produced by stomach epithelial cells and leads to exceptionally high rates of cancer [Guilford, P. et al. (1998) Nature 392, 402–405]. The project is a unique partnership between the family and a research team led by Parry Guilford at the University of Otago in New Zealand. Before work started, the family spoke at length with Guilford to ensure that their cultural beliefs would be respected. ‘In Maori culture, body parts represent the embodiment of the family tree and so are sacred. The family’s requests were easy to accommodate: we stored all their body samples and DNA in a specially designated area; we agreed never to send samples or DNA oversees; and we promised complete confidentiality’, explains Guilford. Linkage analysis of DNA from as many family members as possible was performed using a candidate gene approach, and several candidates were identified, including the E-cad gene. Other research groups have identified E-cad as the main adhesion molecule of epithelia. It has been implicated in carcinogenesis because it is frequently lost in human epithelial cancers. Loss of E-cad function is thought to contribute to progression in breast cancer and other solid tumours by increasing proliferation, invasion and/or metastasis, and reduced E-cad expression has been associated with tumour growth and metastatic spread to the lymph nodes in many types of cancer. Another paper in Nature, published only two weeks before Guilford’s report, showed that loss of E-cadherin-mediated cell adhesion is one rate-limiting step in the progression from adenoma (benign epithelial tumour) to carcinoma (invasive epithelial cancer) [Perl, A.K. et al. (1998) Nature 392, 190–193)]. Guilford’s team was, therefore, not surprised to find that many members of the Maori family in question did indeed have a mutation in the E-cad gene. What did surprise them were the results from two other Maori families with abnormally high rates of stomach cancer. Again, a mutation in the E-cad gene seemed to be responsible, but the damage occurred in two completely different regions of the gene. ‘We had previously assumed that all three families would carry the same mutation and we spent a lot of time tracking down medical records and data on family trees to try to show a connection. We now know that the three mutations must have arisen spontaneously and independently,’says Guilford. Now that the genetic cause of their high incidence of cancer has been found, the family faces some tough choices in the years ahead. The time has come for researchers to start testing samples from the surviving members to find out who carries the mutation and who does not. Family members have expressed their desire to know, and the team is working with the full back-up of genetic counsellors. ‘It is an agonising situation,’ comments Guilford, ‘We know that 7 out of 10 people who carry the mutation develop stomach cancer. Currently there is no preventative treatment and the treatment once a cancer is detected – removing the stomach by surgery – is crude to say the least.’ In the short term, family members are being offered clinical surveillance every six months. If the cancer is caught early, before it spreads to other tissues, the prognosis is better. The next step is to look at ways to delay the onset of cancer in mutation carriers. The three people in ten who carry the mutation but show no signs of cancer provide some hope: the team plans to compare them with affected family members for differences in diet, lifestyle, level of Helicobacter pylori infection (a major risk factor for stomach cancer) and whether they are prone to ulcers. ‘We can eliminate H. pylori infection, if it is present, and we can advise on diets and treatments to avoid ulcers. This is particularly important because the natural healing process that occurs at the margin of ulcers involves a reduction in the E-cad expression of stomach epithelial cells. This allows epithelial cells to migrate across the wound but, if small benign tumours happen to be in that area, this could result in their conversion to malignant growths.’ There are also a number of compounds that upgrade the levels of E-cad expressed in cells. Usually, the mutation occurs in only one allele of the gene, leaving one functional allele. If this can be encouraged to express more E-cad to make up for its faulty counterpart, the onset of cancer might be delayed significantly; even if the cells were to become malignant by some other mechanism, increasing the expression of E-cad should act as a ‘restraining influence’ that would reduce their metastatic potential. One of the most likely candidates for prophylactic drug therapy is tamoxifen. In the longer term, the team is optimistic that gene therapy will be developed within five years. They plan to reverse the existing mutation using the cells’inherent DNA repair machinery. There is much work to be done – not least the development of an efficient delivery system to ensure that most of the stem cells in the crypts can be reached. But how does Guilford think gene therapy fits with the cultural beliefs of the Maori family members? ‘Many people from the family started out with quite a high level of suspicion about genetics but they are equal partners in this project and most are now very well educated in the science and the ethical issues involved. We will continue to take things carefully and slowly. The bottom line continues to be that the individual has the right to choose.’ Kathryn Senior 276 N e w s MOLECULAR MEDICINE TODAY, JULY 1998 Copyright ©1998 Elsevier Science Ltd. All rights reserved. 1357 - 4310/98/$19.00 Maori family initiates successful search for stomach cancer gene Figure 1. E-cadherin and cell–cell adhesion. E-cadherin is a transmembrane molecule that can form homophilic associations with E-cadherin molecules on adjacent cells. Intracellularly, it interacts with the actin cytoskeleton via a, b and g catenin. Plasma membranes Intracellular environment Intracellular environment Extracellular environment E-cadherin Catenins Actin cytoskeleton β α γ

Maori family initiates successful search for stomach cancer gene

Embed Size (px)

Citation preview

Page 1: Maori family initiates successful search for stomach cancer gene

After losing 25 of its members to stomach cancerin 30 years, a Maori family put aside traditionalsuperstitions and contacted laboratoriesthroughout New Zealand to obtain a scientificexplanation. The study they initiated has identifieda germline mutation in the gene that codes for E-cadherin (E-cad), an epithelial cell adhesionmolecule (Fig. 1). The mutation causes a reductionin the amount of functional E-cadherin producedby stomach epithelial cells and leads toexceptionally high rates of cancer [Guilford, P. etal. (1998) Nature 392, 402–405].

The project is a unique partnership between thefamily and a research team led by Parry Guilford atthe University of Otago in New Zealand. Beforework started, the family spoke at length withGuilford to ensure that their cultural beliefs wouldbe respected. ‘In Maori culture, body parts representthe embodiment of the family tree and so are sacred.The family’s requests were easy to accommodate:we stored all their body samples and DNA in aspecially designated area; we agreed never to sendsamples or DNA oversees; and we promisedcomplete confidentiality’, explains Guilford.

Linkage analysis of DNA from as many familymembers as possible was performed using acandidate gene approach, and several candidateswere identified, including the E-cad gene. Otherresearch groups have identified E-cad as the mainadhesion molecule of epithelia. It has beenimplicated in carcinogenesis because it is frequentlylost in human epithelial cancers. Loss of E-cadfunction is thought to contribute to progression inbreast cancer and other solid tumours by increasing

proliferation, invasion and/or metastasis, andreduced E-cad expression has been associated withtumour growth and metastatic spread to the lymphnodes in many types of cancer. Another paper inNature, published only two weeks before Guilford’sreport, showed that loss of E-cadherin-mediated celladhesion is one rate-limiting step in the progressionfrom adenoma (benign epithelial tumour) tocarcinoma (invasive epithelial cancer) [Perl, A.K. etal. (1998) Nature 392, 190–193)].

Guilford’s team was, therefore, not surprised tofind that many members of the Maori family inquestion did indeed have a mutation in the E-cadgene. What did surprise them were the results fromtwo other Maori families with abnormally high ratesof stomach cancer. Again, a mutation in the E-cadgene seemed to be responsible, but the damageoccurred in two completely different regions of thegene. ‘We had previously assumed that all threefamilies would carry the same mutation and wespent a lot of time tracking down medical recordsand data on family trees to try to show a connection.We now know that the three mutations must havearisen spontaneously and independently,’ saysGuilford.

Now that the genetic cause of their highincidence of cancer has been found, the family facessome tough choices in the years ahead. The time hascome for researchers to start testing samples fromthe surviving members to find out who carries themutation and who does not. Family members haveexpressed their desire to know, and the team isworking with the full back-up of geneticcounsellors. ‘It is an agonising situation,’ comments

Guilford, ‘We know that 7 out of 10 people whocarry the mutation develop stomach cancer.Currently there is no preventative treatment and thetreatment once a cancer is detected – removing thestomach by surgery – is crude to say the least.’

In the short term, family members are beingoffered clinical surveillance every six months. If thecancer is caught early, before it spreads to othertissues, the prognosis is better. The next step is tolook at ways to delay the onset of cancer in mutationcarriers. The three people in ten who carry themutation but show no signs of cancer provide somehope: the team plans to compare them with affectedfamily members for differences in diet, lifestyle,level of Helicobacter pylori infection (a major riskfactor for stomach cancer) and whether they areprone to ulcers. ‘We can eliminate H. pyloriinfection, if it is present, and we can advise on dietsand treatments to avoid ulcers. This is particularlyimportant because the natural healing process thatoccurs at the margin of ulcers involves a reductionin the E-cad expression of stomach epithelial cells.This allows epithelial cells to migrate across thewound but, if small benign tumours happen to be inthat area, this could result in their conversion tomalignant growths.’

There are also a number of compounds thatupgrade the levels of E-cad expressed in cells.Usually, the mutation occurs in only one allele of thegene, leaving one functional allele. If this can beencouraged to express more E-cad to make up forits faulty counterpart, the onset of cancer might bedelayed significantly; even if the cells were tobecome malignant by some other mechanism,increasing the expression of E-cad should act as a‘restraining influence’ that would reduce theirmetastatic potential. One of the most likelycandidates for prophylactic drug therapy istamoxifen.

In the longer term, the team is optimistic thatgene therapy will be developed within five years.They plan to reverse the existing mutation using thecells’ inherent DNA repair machinery. There ismuch work to be done – not least the developmentof an efficient delivery system to ensure that most ofthe stem cells in the crypts can be reached. But howdoes Guilford think gene therapy fits with thecultural beliefs of the Maori family members?

‘Many people from the family started out withquite a high level of suspicion about genetics butthey are equal partners in this project and most arenow very well educated in the science and theethical issues involved. We will continue to takethings carefully and slowly. The bottom linecontinues to be that the individual has the right tochoose.’

Kathryn Senior

276

N e w s MOLECULAR MEDICINE TODAY, JULY 1998

Copyright ©1998 Elsevier Science Ltd. All rights reserved. 1357 - 4310/98/$19.00

Maori family initiates successful searchfor stomach cancer gene

Figure 1. E-cadherin and cell–cell adhesion. E-cadherin is a transmembrane molecule that can form homophilic associations with E-cadherin molecules on adjacent cells. Intracellularly, it interacts with theactin cytoskeleton via a, b and g catenin.

Plasma membranes

Intracellularenvironment Intracellular

environment

Extracellularenvironment

E-cadherin Catenins

Actincytoskeleton

βα

γ